Biocodex Nordics
Biocodex Nordics is a healthcare company active in Finland and the Baltic countries and is part of the multinational Biocodex Group.
OUR HISTORY
Biocodex is a family-owned multinational pharmaceutical company founded in France in 1953. The initial focus of the company was gastroenterology featuring a unique probiotic: Saccharomyces boulardii CNCM I-745®, the first probiotic drug.
Biocodex’s story began in 1923 in Indochina, where Henri Boulard invented Saccharomyces boulardii CNCM I-745® yeast. In 1953, the Hublot and Vallet families acquired the rights to Henri Boulard’s yeast strain and fermentation process.
In 1961, thanks to clinical evidence, lyophilized Saccharomyces boulardii CNCM I-745® was registered as a drug and commercialized as such. Since then, Biocodex has expanded its historical legitimacy and expertise in gut microbiota.
For many years, on top of gastroenterology, Biocodex has also developed scientific expertise in other therapeutic areas such as pain, neurology and general practice.
Biocodex’s main competence is the development of the microflora and its flagship product Saccharomyces boulardii CNCM I-745® and the launch of new innovative probiotics.
Biocodex currently operates in several different therapy areas in over 100 countries. We have 17 own subsidiaries, but we also operate through our partners.
The global turnover is EUR 634 million (2024) and Biocodex employs over 1,800 people representing 30 different nationalities.
Biocodex Nordics has a turnover of approximately EUR 23 million and we are 80 in four countries.
Biocodex Nordics has its’ headquarter in Espoo, Finland. The focus areas are microbiota, women health, orphan drugs and neuropsychiatry.
